 Brian Montague
Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prisoners | 10 | 2020 | 124 | 2.430 |
Why?
| | Prisons | 8 | 2020 | 72 | 1.770 |
Why?
| | Emergency Responders | 2 | 2022 | 33 | 1.580 |
Why?
| | HIV Infections | 20 | 2020 | 2470 | 1.560 |
Why?
| | Immunoglobulin A | 2 | 2022 | 171 | 0.920 |
Why?
| | Asymptomatic Infections | 1 | 2022 | 21 | 0.790 |
Why?
| | Antibodies, Viral | 2 | 2022 | 522 | 0.790 |
Why?
| | Viral Load | 3 | 2018 | 405 | 0.780 |
Why?
| | Patient Acceptance of Health Care | 3 | 2018 | 679 | 0.720 |
Why?
| | Continuity of Patient Care | 3 | 2018 | 254 | 0.680 |
Why?
| | Rhode Island | 10 | 2018 | 23 | 0.670 |
Why?
| | Communicable Disease Control | 2 | 2014 | 67 | 0.540 |
Why?
| | Anti-Retroviral Agents | 2 | 2016 | 207 | 0.530 |
Why?
| | Hepatitis C | 2 | 2015 | 219 | 0.510 |
Why?
| | Patient Identification Systems | 1 | 2015 | 17 | 0.510 |
Why?
| | Antiviral Agents | 3 | 2021 | 647 | 0.500 |
Why?
| | Medical Record Linkage | 1 | 2015 | 53 | 0.480 |
Why?
| | Telemedicine | 2 | 2020 | 665 | 0.480 |
Why?
| | Public-Private Sector Partnerships | 1 | 2014 | 43 | 0.440 |
Why?
| | Vulnerable Populations | 2 | 2018 | 133 | 0.390 |
Why?
| | Hepatitis B Vaccines | 1 | 2012 | 46 | 0.390 |
Why?
| | Hepatitis B | 1 | 2012 | 51 | 0.380 |
Why?
| | Public Health Administration | 1 | 2012 | 75 | 0.380 |
Why?
| | Tuberculosis | 1 | 2014 | 241 | 0.370 |
Why?
| | Health Resources | 1 | 2011 | 122 | 0.350 |
Why?
| | Vaccination | 2 | 2022 | 1205 | 0.340 |
Why?
| | Mass Screening | 6 | 2020 | 1011 | 0.330 |
Why?
| | Immunoglobulin G | 2 | 2022 | 776 | 0.300 |
Why?
| | Hyperkalemia | 1 | 2008 | 26 | 0.290 |
Why?
| | Humans | 37 | 2023 | 114937 | 0.280 |
Why?
| | Drug Industry | 1 | 2008 | 104 | 0.280 |
Why?
| | Health Services Accessibility | 4 | 2020 | 765 | 0.260 |
Why?
| | Interprofessional Relations | 1 | 2008 | 251 | 0.260 |
Why?
| | Community Health Services | 3 | 2016 | 212 | 0.250 |
Why?
| | Health Promotion | 1 | 2011 | 686 | 0.250 |
Why?
| | Electrocardiography | 1 | 2008 | 562 | 0.240 |
Why?
| | AIDS Serodiagnosis | 2 | 2014 | 29 | 0.230 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.220 |
Why?
| | Adult | 14 | 2021 | 30608 | 0.200 |
Why?
| | Meningitis | 1 | 2023 | 74 | 0.200 |
Why?
| | Masks | 1 | 2022 | 46 | 0.200 |
Why?
| | North Carolina | 3 | 2018 | 97 | 0.200 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 98 | 0.190 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2015 | 256 | 0.190 |
Why?
| | Retrospective Studies | 7 | 2022 | 12544 | 0.180 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 668 | 0.170 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 221 | 0.170 |
Why?
| | Teicoplanin | 1 | 2019 | 17 | 0.160 |
Why?
| | Male | 17 | 2021 | 55663 | 0.160 |
Why?
| | Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 1 | 0.160 |
Why?
| | Klebsiella Infections | 1 | 2019 | 23 | 0.160 |
Why?
| | Darunavir | 1 | 2019 | 17 | 0.160 |
Why?
| | beta-Lactamases | 1 | 2019 | 26 | 0.160 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 28 | 0.160 |
Why?
| | Klebsiella pneumoniae | 1 | 2019 | 41 | 0.160 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 61 | 0.160 |
Why?
| | Female | 17 | 2021 | 59581 | 0.160 |
Why?
| | Drug Users | 2 | 2020 | 41 | 0.160 |
Why?
| | Internship and Residency | 1 | 2008 | 944 | 0.160 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 336 | 0.160 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 64 | 0.160 |
Why?
| | Patient Dropouts | 1 | 2018 | 66 | 0.150 |
Why?
| | HIV Integrase Inhibitors | 1 | 2019 | 62 | 0.150 |
Why?
| | Socioeconomic Factors | 3 | 2018 | 1081 | 0.150 |
Why?
| | Middle Aged | 10 | 2021 | 26806 | 0.140 |
Why?
| | Aged | 8 | 2021 | 19122 | 0.140 |
Why?
| | Bacteremia | 1 | 2019 | 159 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 666 | 0.140 |
Why?
| | Quality Improvement | 2 | 2014 | 954 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2019 | 159 | 0.140 |
Why?
| | Marijuana Use | 1 | 2019 | 167 | 0.130 |
Why?
| | Referral and Consultation | 3 | 2016 | 634 | 0.130 |
Why?
| | Budgets | 1 | 2015 | 14 | 0.130 |
Why?
| | United States | 6 | 2020 | 12211 | 0.130 |
Why?
| | Biostatistics | 1 | 2015 | 16 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 2 | 2014 | 99 | 0.130 |
Why?
| | State Government | 1 | 2015 | 41 | 0.120 |
Why?
| | Confidentiality | 1 | 2015 | 67 | 0.120 |
Why?
| | Population Surveillance | 1 | 2018 | 392 | 0.120 |
Why?
| | Pilot Projects | 1 | 2019 | 1372 | 0.120 |
Why?
| | Drug Costs | 1 | 2015 | 91 | 0.120 |
Why?
| | Young Adult | 7 | 2021 | 10478 | 0.120 |
Why?
| | Incidence | 3 | 2021 | 2316 | 0.120 |
Why?
| | Adolescent | 7 | 2021 | 17829 | 0.120 |
Why?
| | Tuberculosis, Meningeal | 1 | 2014 | 6 | 0.120 |
Why?
| | Healthcare Financing | 1 | 2014 | 6 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2015 | 147 | 0.110 |
Why?
| | Prevalence | 2 | 2020 | 2252 | 0.110 |
Why?
| | Tuberculin Test | 1 | 2014 | 32 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2021 | 6364 | 0.110 |
Why?
| | Interferon-gamma Release Tests | 1 | 2014 | 26 | 0.110 |
Why?
| | Bayes Theorem | 1 | 2015 | 331 | 0.110 |
Why?
| | Drugs, Generic | 1 | 2013 | 18 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 413 | 0.110 |
Why?
| | Colorado | 2 | 2019 | 4091 | 0.110 |
Why?
| | Epidemics | 1 | 2014 | 69 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2019 | 834 | 0.100 |
Why?
| | Antitubercular Agents | 1 | 2014 | 169 | 0.100 |
Why?
| | Prospective Studies | 2 | 2022 | 6218 | 0.100 |
Why?
| | Sexually Transmitted Diseases | 1 | 2014 | 155 | 0.100 |
Why?
| | Refugees | 1 | 2012 | 53 | 0.100 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 107 | 0.100 |
Why?
| | Sex Work | 1 | 2011 | 18 | 0.100 |
Why?
| | Models, Statistical | 1 | 2015 | 604 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1400 | 0.090 |
Why?
| | Computer Simulation | 1 | 2015 | 880 | 0.090 |
Why?
| | Drug Utilization | 1 | 2011 | 167 | 0.090 |
Why?
| | Criminal Law | 1 | 2010 | 28 | 0.090 |
Why?
| | Sexual Behavior | 1 | 2014 | 440 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1477 | 0.090 |
Why?
| | Homosexuality, Male | 1 | 2011 | 170 | 0.090 |
Why?
| | Insurance, Health | 1 | 2012 | 244 | 0.080 |
Why?
| | Time Factors | 2 | 2020 | 6125 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1700 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 947 | 0.080 |
Why?
| | Texas | 2 | 2020 | 188 | 0.080 |
Why?
| | Patient Compliance | 1 | 2012 | 526 | 0.080 |
Why?
| | Risk Factors | 3 | 2020 | 8637 | 0.070 |
Why?
| | Minority Groups | 1 | 2009 | 228 | 0.070 |
Why?
| | Brain | 1 | 2019 | 2372 | 0.070 |
Why?
| | Program Evaluation | 1 | 2011 | 824 | 0.070 |
Why?
| | Family | 1 | 2010 | 590 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 1813 | 0.060 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 50 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 90 | 0.050 |
Why?
| | Forecasting | 2 | 2014 | 333 | 0.050 |
Why?
| | Curriculum | 1 | 2008 | 845 | 0.050 |
Why?
| | Particulate Matter | 1 | 2023 | 185 | 0.050 |
Why?
| | Assisted Living Facilities | 1 | 2021 | 9 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2021 | 73 | 0.050 |
Why?
| | Drug Approval | 1 | 2021 | 78 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 372 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 121 | 0.040 |
Why?
| | Off-Label Use | 1 | 2019 | 51 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 546 | 0.040 |
Why?
| | Oxazines | 1 | 2019 | 25 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 4903 | 0.040 |
Why?
| | India | 1 | 2019 | 134 | 0.040 |
Why?
| | Pyridones | 1 | 2019 | 124 | 0.040 |
Why?
| | Risk-Taking | 1 | 2020 | 333 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2021 | 1663 | 0.040 |
Why?
| | Piperazines | 1 | 2019 | 313 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 954 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 574 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1220 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 949 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 581 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1593 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 1754 | 0.030 |
Why?
| | Liberia | 1 | 2014 | 6 | 0.030 |
Why?
| | Endemic Diseases | 1 | 2014 | 23 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2014 | 127 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2542 | 0.030 |
Why?
| | Interinstitutional Relations | 1 | 2014 | 55 | 0.030 |
Why?
| | Long-Term Care | 1 | 2014 | 77 | 0.030 |
Why?
| | Cost Savings | 1 | 2013 | 74 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 773 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 9086 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 336 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 185 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2012 | 36 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 9105 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2014 | 202 | 0.030 |
Why?
| | Appointments and Schedules | 1 | 2012 | 73 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 244 | 0.030 |
Why?
| | Cost of Illness | 1 | 2014 | 254 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3008 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 383 | 0.020 |
Why?
| | Qualitative Research | 1 | 2015 | 936 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2014 | 479 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 1844 | 0.020 |
Why?
| | Unsafe Sex | 1 | 2009 | 58 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5035 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4635 | 0.020 |
Why?
| | Social Support | 1 | 2010 | 528 | 0.020 |
Why?
| | Child | 2 | 2019 | 18366 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 675 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2382 | 0.020 |
Why?
| | Infant | 1 | 2019 | 7937 | 0.020 |
Why?
| | Risk Assessment | 1 | 2014 | 2975 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2326 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1183 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3053 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 4407 | 0.010 |
Why?
|
|
Montague's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|